Seres Therapeutics, Inc. SEC filings MCRB
Seres Therapeutics, Inc. has 724 filings in SEC EDGAR's recent list, going back to Jun 9, 2014. Its latest annual report, Form 10-K, was filed on Mar 12, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 27, 2026 | — |
| DEF 14A | Proxy statement | Apr 27, 2026 | Jun 9, 2026 |
| DEFA14A | Additional proxy material | Apr 4, 2025 | — |
| DEF 14A | Proxy statement | Mar 13, 2025 | Mar 13, 2025 |
| PRE 14A | Preliminary proxy statement | Mar 3, 2025 | Mar 3, 2025 |
| DEFA14A | Additional proxy material | Sep 12, 2024 | — |
| DEFM14A | Filing | Aug 26, 2024 | — |
| DEFA14A | Additional proxy material | Aug 15, 2024 | — |
| PREM14A | Filing | Aug 15, 2024 | Aug 15, 2024 |
| DEFA14A | Additional proxy material | Aug 13, 2024 | — |
| DEFA14A | Additional proxy material | Aug 13, 2024 | — |
| DEFA14A | Additional proxy material | Aug 7, 2024 | — |
| DEFA14A | Additional proxy material | Aug 7, 2024 | — |
| DEFA14A | Additional proxy material | Aug 6, 2024 | — |
| DEFA14A | Additional proxy material | Aug 6, 2024 | — |
| DEFA14A | Additional proxy material | Aug 6, 2024 | — |
| DEF 14A | Proxy statement | Mar 5, 2024 | Mar 5, 2024 |
| PRE 14A | Preliminary proxy statement | Feb 23, 2024 | Feb 22, 2024 |
| DEFA14A | Additional proxy material | Apr 25, 2023 | — |
| DEF 14A | Proxy statement | Apr 25, 2023 | — |
| PRE 14A | Preliminary proxy statement | Apr 14, 2023 | — |
| DEFA14A | Additional proxy material | Apr 29, 2022 | — |
| DEF 14A | Proxy statement | Apr 29, 2022 | Jun 22, 2022 |
| DEFA14A | Additional proxy material | Apr 30, 2021 | — |
| DEF 14A | Proxy statement | Apr 30, 2021 | Jun 16, 2021 |
| DEFA14A | Additional proxy material | Apr 30, 2020 | — |
| DEF 14A | Proxy statement | Apr 30, 2020 | Jun 18, 2020 |
| DEFA14A | Additional proxy material | Apr 30, 2019 | — |
| DEF 14A | Proxy statement | Apr 30, 2019 | Jun 13, 2019 |
| DEFA14A | Additional proxy material | Apr 30, 2018 | — |
| DEF 14A | Proxy statement | Apr 30, 2018 | Jun 26, 2018 |
| DEFA14A | Additional proxy material | May 1, 2017 | — |
| DEF 14A | Proxy statement | May 1, 2017 | Jun 20, 2017 |
| DEFA14A | Additional proxy material | Apr 28, 2016 | — |
| DEF 14A | Proxy statement | Apr 28, 2016 | Jun 15, 2016 |
Showing 35 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MCRB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1609809
- Former names
- Seres Therapeutics, Inc. (until Nov 4, 2026); Seres Health, Inc. (until May 14, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.